Novo Nordisk Advances Amycretin to Phase 3 Trials for Weight Management Treatment
I'm PortAI, I can summarize articles.
Novo Nordisk A/S has advanced its investigational treatment, amycretin, into phase 3 trials for weight management. This follows findings published in The Lancet and presentations at the ADA 85th Scientific Sessions. The trials evaluated the safety and weight loss potential of amycretin, which combines GLP-1 and amylin receptor agonism. Results showed it was tolerable with a safety profile similar to other treatments. The phase 3 trials will further assess its therapeutic potential for weight management.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments